>
> I guess I was thinking if you make re-align, it's for...
> - cost cutting
> - improve revenues
>
Exactly! (and it's the point that I wanted to discuss with you today even before I saw your new message)
I'm familiar with Golden's previous financial statements. Whenever they sold vehicles, they always showed a GAIN.
Thus, if they are re-aligning routes and (from the most recent 10K) "increasing distribution through independent operators and distributors", I would assume that they will be selling vehicles for a GAIN.
Previously, (I assume) they sold vehicles that were beyond use to the company (i.e. old, too many miles). For a GAIN. If Golden is now selling vehicles because routes are re-aligning, (I assume) they will sell vehicles that are in better condition. For a better GAIN.
Less vehicles = less gasoline, insurance, payroll, maintenance, etc. expenses. Thus, REDUCED COSTS to the balance sheets.
How in the world can Golden possibly claim a one-time charge for re-aligning routes?
I have only two (sarcastic) thoughts:
1. Maybe distributors work like "hypermarkets". If a company wants its products to be sold in a hypermarket (sorry, I don't know the big hypermarket chains in the U.S.), the company must pay a fee to the hypermarket to obtain shelf space. Maybe that's Golden's one-time charge for re-aligning the eastern routes--Golden must pay the distributors to sell Golden's products (Ah, don't you just love the Mafia version of capitalism? )
2. Severance pay for laid-off Golden drivers. For the sake of discussion, let's say that $0.06 of the $0.07 cost against earnings is for route re-alignment (again, Golden didn't tell us how the $0.07 is divided).
$0.06 X 11.78 million shares = $706,800
Of course, we have no idea how many drivers got laid off, if any. If two drivers got laid off, they are very expensive drivers.
As usual, though, we must wait for the 10-Q in the hopes of some explanation.
Recent GLDC News
- TSX Venture Exchange Stock Maintenance Bulletins • PR Newswire (Canada) • 12/29/2023 10:51:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM